Barré et al. designed and synthetized dihydroquinoline 72 (Figure 13) as a promising bio-oxidizable prodrug to delivery both cholinesterase (ChE) and DYRK1A inhibitors for AD treatment [159]. Here, BCHE is linked to Alzheimer disease.